Corcept Therapeutics Incorporated Cash Flow Conversion Efficiency
Corcept Therapeutics Incorporated cash flow conversion efficiency. Based on the latest financial reports, Corcept Therapeutics Incorporated (CORT) has a cash flow conversion efficiency ratio of -0.026x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.77 Million) by net assets ($637.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Corcept Therapeutics Incorporated (2003–2025)
Cash flow conversion efficiency of Corcept Therapeutics Incorporated from 2003 to 2025. This chart illustrates how Corcept Therapeutics Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Corcept Therapeutics Incorporated stock price for real-time trading data and today's change.
Corcept Therapeutics Incorporated Cash Flow Conversion Ratio Explained
Corcept Therapeutics Incorporated cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Corcept Therapeutics Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Corcept Therapeutics Incorporated ranked by their cash flow conversion efficiency. Also see Corcept Therapeutics Incorporated (CORT) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ultrapar Participações S.A
F:UGR
|
0.134x |
|
JCHX Mining Management Co Ltd
SHG:603979
|
0.084x |
|
Beta Technologies, Inc.
NYSE:BETA
|
-0.055x |
|
Gland Pharma Limited
NSE:GLAND
|
0.057x |
|
BRF S.A
SA:BRFS3
|
0.142x |
|
Chailease Holding Co Ltd
TW:5871
|
0.009x |
|
Taylor Morn Home
NYSE:TMHC
|
-0.002x |
|
Varonis Systems
NASDAQ:VRNS
|
0.056x |
Annual Cash Flow Conversion Efficiency for Corcept Therapeutics Incorporated (2003–2025)
The table below shows the annual cash flow conversion efficiency of Corcept Therapeutics Incorporated from 2003 to 2025. Review free cash flow generation of Corcept Therapeutics Incorporated to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $647.80 Million | $142.00 Million | 0.219x | -24.79% |
| 2024-12-31 | $679.59 Million | $198.07 Million | 0.291x | +16.25% |
| 2023-12-31 | $506.70 Million | $127.04 Million | 0.251x | +4.57% |
| 2022-12-31 | $501.84 Million | $120.32 Million | 0.240x | -46.33% |
| 2021-12-31 | $375.81 Million | $167.89 Million | 0.447x | +53.85% |
| 2020-12-31 | $523.34 Million | $151.97 Million | 0.290x | -20.81% |
| 2019-12-31 | $371.18 Million | $136.12 Million | 0.367x | -12.53% |
| 2018-12-31 | $275.88 Million | $115.67 Million | 0.419x | +31.39% |
| 2017-12-31 | $190.97 Million | $60.94 Million | 0.319x | -28.21% |
| 2016-12-31 | $41.38 Million | $18.39 Million | 0.444x | +162.67% |
| 2015-12-31 | $18.50 Million | $3.13 Million | 0.169x | -97.91% |
| 2014-12-31 | $-3.39 Million | $-27.38 Million | 8.080x | +558.26% |
| 2013-12-31 | $21.02 Million | $-37.06 Million | -1.763x | -202.41% |
| 2012-12-31 | $61.78 Million | $-36.02 Million | -0.583x | +25.93% |
| 2011-12-31 | $34.81 Million | $-27.40 Million | -0.787x | +24.96% |
| 2010-12-31 | $21.24 Million | $-22.29 Million | -1.049x | -28.98% |
| 2009-12-31 | $22.09 Million | $-17.97 Million | -0.813x | +25.11% |
| 2008-12-31 | $16.91 Million | $-18.36 Million | -1.086x | -45.95% |
| 2007-12-31 | $14.73 Million | $-10.96 Million | -0.744x | +79.63% |
| 2006-12-31 | $6.36 Million | $-23.24 Million | -3.654x | -463.80% |
| 2005-12-31 | $26.59 Million | $-17.23 Million | -0.648x | -117.07% |
| 2004-12-31 | $45.95 Million | $-13.72 Million | -0.299x | +69.43% |
| 2003-12-31 | $10.24 Million | $-10.00 Million | -0.977x | -- |
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type … Read more